

Duane A Mitchell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/502013/publications.pdf>

Version: 2024-02-01

34
papers

3,412
citations

279798

23
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

3887
citing authors

#	ARTICLE	IF	CITATIONS
1	Adoptive cell therapy for glioma. , 2022, , 73-89.		1
2	Is There a Role for Immunotherapy in Central Nervous System Cancers?. Hematology/Oncology Clinics of North America, 2022, 36, 237-252.	2.2	5
3	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	13.2	21
4	Effects of immune checkpoint blockade on antigen-specific CD8 ⁺ T cells for use in adoptive cellular therapy. Microbiology and Immunology, 2022, 66, 201-211.	1.4	6
5	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clinical Cancer Research, 2020, 26, 5297-5303.	7.0	67
6	Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. Clinical Cancer Research, 2020, 26, 5689-5700.	7.0	26
7	Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research, 2020, 80, 499-509.	0.9	68
8	Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy. Science Advances, 2019, 5, eaav9879.	10.3	17
9	Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. Stem Cells, 2019, 37, 166-175.	3.2	17
10	Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. Clinical Cancer Research, 2018, 24, 3955-3966.	7.0	34
11	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Research, 2018, 78, 256-264.	0.9	82
12	Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma. EMBO Journal, 2018, 37, .	7.8	118
13	Lin ⁺ CCR2 ⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. Nature Communications, 2018, 9, 4313.	12.8	32
14	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research, 2017, 23, 1898-1909.	7.0	215
15	Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM. International Journal of Cancer, 2017, 141, 1434-1444.	5.1	70
16	CD4 ⁺ and Perivascular Foxp3 ⁺ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression. Frontiers in Immunology, 2017, 8, 1451.	4.8	47
17	Migration of dendritic cells to the lymph nodes and its enhancement to drive anti-tumor responses. Critical Reviews in Oncology/Hematology, 2016, 107, 100-110.	4.4	43
18	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research, 2016, 22, 582-595.	7.0	88

#	ARTICLE	IF	CITATIONS
19	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. <i>OncolImmunology</i> , 2015, 4, e994374.	4.6	41
20	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature</i> , 2015, 519, 366-369.	27.8	429
21	Vaccination strategies for neuro-oncology: Table 1.. <i>Neuro-Oncology</i> , 2015, 17, vii15-vii25.	1.2	25
22	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 2684-2694.	7.0	74
23	Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody. <i>Cancer Immunology Research</i> , 2013, 1, 163-167.	3.4	61
24	Monoclonal antibody blockade of IL-2 receptor β during lymphopenia selectively depletes regulatory T cells in mice and humans. <i>Blood</i> , 2011, 118, 3003-3012.	1.4	104
25	Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. <i>Neuro-Oncology</i> , 2011, 13, 324-333.	1.2	306
26	Reply to M.S. Lesniak. <i>Journal of Clinical Oncology</i> , 2011, 29, 3105-3106.	1.6	9
27	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4722-4729.	1.6	702
28	An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2773-2779.	4.1	262
29	Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors. <i>Neurotherapeutics</i> , 2009, 6, 527-538.	4.4	37
30	Selective Modification of Antigen-Specific T Cells by RNA Electroporation. <i>Human Gene Therapy</i> , 2008, 19, 511-521.	2.7	39
31	Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 10-18.	1.2	323
32	Temozolomide as a vaccine adjuvant in GBM. <i>Journal of Clinical Oncology</i> , 2007, 25, 2020-2020.	1.6	14
33	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 161-176.	2.9	6
34	Adoptive Immunotherapy for Malignant Glioma. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 157-166.	2.0	21